Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "Proof of concept" patented technology

Proof of concept (PoC) is a realization of a certain method or idea in order to demonstrate its feasibility, or a demonstration in principle with the aim of verifying that some concept or theory has practical potential. A proof of concept is usually small and may or may not be complete.

Context aware phonebook

When interacting and talking with each other, humans are quite successful at conveying information and reacting appropriately. That is, they are able to interpret situational information which in most cases is only implicitly given. This ability is in stark contrast to most of the current state-of-the-art computer and telecommunications systems, which in large are unaware of this context information. Consequently, there has recently been great interest in making applications more context-aware so that they can adapt to different situations and be more receptive to user's needs.
The purpose of this project was to explore how one through examining different kinds of context information can find ways to automatically set a user's presence status. This presence status is useful as it allows for a person to decide whether it is appropriate to initiate communication or not. Further, it was the mission of this project to review how a policy-based approach could be use together with the mentioned aggregated presence status to increase user personalisation of communication. Finally, the project set out to show how one can model and implement such a context-aware system using Ericsson's service creation framework; ServiceFrame.
The project used a model-driven approach (MDA) in which most of the effort went into modelling the functionality of the system using formal UML2.0 models and then transform these into code using code generation tools and MDA viewpoints. During the modelling of the system, it was decided to examine user's context information and from this classify the user's aggregated presence status by utilising a supervised learning classifier. In a proof-of-concept solution, the probabilistic classifier, Naïve Bayes, proved to be an extremely fast and accurate classifier which should be considered as a strong option in any future implementations of the system. Personalisation of communications by design was achieved both through allowing completely personal classification rules, as well as through a policy approach. This policy approach consisted of letting a user construct a personal prioritising of his or hers terminals based on his or her aggregated presence status. It is suggested to expand this approach by also taking the group membership of the entity which requests the user information into account.
Using supervised learning makes sure the system is not to be solely dependent on any particular context data sensor but rather having the ability to adapt to an ever-changing environment. With the expected explosion of context sensors in areas such as ubiquitous computing [15], this ability to adapt will become increasingly important in future context-aware systems. In addition to this flexibility, the use of supervised learning also introduces the ability to classify completely unknown scenarios. This means that even if the classifier encounters a new scenario which is has never seen before, it tries to predict a status based on the underlying previous data. It stated that these predictions often have a high degree of accuracy with the right training data.
The system used the agent oriented architecture, which it is stated has a good support for personalisation as agents generally are used to represent entities in the real world (e.g. users). Through this approach, the system allows for a completely personal classification of a user's current context. By doing so, it is acknowledged that pre-defined rules does not fit everyone, but should be adapted to give each person a high degree of personalisation.
Owner:CISCO TECH INC

Method for realizing Android system vulnerability detection on the basis of vulnerability poc (Proof of Concept)

The invention discloses a method for realizing Android system vulnerability detection on the basis of a vulnerability poc (Proof of Concept). The method comprises the following steps that: establishing a vulnerability description file and a vulnerability library; developing an APP (Application) program; installing the APP program on a detected Android terminal; through an ADB (Android Debug Bridge), establishing a communication link with the APP program through a superior detection system; after the APP program receives a detection starting instruction, starting detection work; according to Android system information, loading a corresponding vulnerability detection unit list by the APP program; executing loaded vulnerability detection units one by one by a vulnerability detection engine, executing a detection task, and collecting a detection result; combining the detection result with the corresponding vulnerability description file by the vulnerability detection engine to generate a final detection report, and returning the final detection report to the superior detection system through the communication link; and deleting the APP program, carrying out disconnection, and finishing detection. By use of the method, the technical problems of low detection efficiency, incomplete detection contents and poor user operation experience in the prior art can be solved, and deficiencies in an existing scheme are made up.
Owner:广州安海信息安全技术有限公司

Method and apparatus for keeping PoC continuous connection handling capacity

The invention discloses a method and an apparatus for keeping proof of concept (PoC) continuous connection handling capacity. According to the method, a state presentation server receives continuous connection service request information from a PoC client and transmits the continuous connection service request information to a policy and charging rules function (PCRF); the PCRF transmits an internet protocol-control area network (IP-CAN) session continuous connection capacity request corresponding to the user information to a gateway GPRS supporting node (GGSN); the GGSN provides a continuous connection capacity to the user through a service GPRS supporting node (SGSN); and the PoC client adaptively adjust a heartbeat cycle of the presentation server in real time according to a network quality situation, so as to guarantee continuous connection of the PoC client. The embodiment of the invention not only can effectively reduce influence of frequent transmission of a conventional heartbeat packet on a network signaling load, but also can realize packet connectivity initiated by the terminal according to the quality of network in which a terminal side is located, thus guaranteeing continuous connection from both network and terminal aspects and enhancing use efficiency and quality of users.
Owner:CHONGQING TELECOMMUNICATION INSTITUTE

Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders

ActiveUS20160331816A1Improved right heart functionDecreased pulmonary vessel wall thicknessPowder deliveryPeptide/protein ingredientsDiseaseUveitis
Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.
Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1

Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products